Inhibitor Therapeutics (INTI) Short term Debt (2013 - 2026)
Inhibitor Therapeutics' (INTI) quarterly Short term Debt came in at $28981.0 in Q1 2026, up 11.52% YoY from $25987.0 in Q1 2025, and up 17.22% on a QoQ basis from $24724.0 in Q4 2025.
Inhibitor Therapeutics (INTI) Short term Debt (2013 - 2026) Analysis & Trends
Inhibitor Therapeutics (INTI) has 4 years of Short term Debt data on file, last reported at $28981.0 in Q1 2026.
- Quarterly Short term Debt rose 11.52% year-over-year to $28981.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28981.0 (up 11.52% YoY) and the FY2025 annual result came in at $24724.0, changed N/A from the prior year.
- Short term Debt advanced to $28981.0 in Q1 2026, from $24724.0 in the prior quarter.
- In the past five years, Short term Debt ranged from a high of $28981.0 in Q1 2026 to a low of $24724.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Inhibitor Therapeutics | 15.64 Mn | 15.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 28,981.00 |
| Dec 31, 2025 | 24,724.00 |
| Sep 30, 2025 | 27,455.00 |
| Jun 30, 2025 | 25,987.00 |
| Mar 31, 2025 | 25,987.00 |
| Dec 31, 2014 | 273,638.00 |
| Sep 30, 2014 | 639,768.00 |
| Jun 30, 2014 | 639,768.00 |
| Mar 31, 2014 | 474,874.00 |
| Dec 31, 2013 | 366,130.00 |
| Sep 30, 2013 | 196,588.00 |